论文部分内容阅读
目的探讨肺癌临床诊断中肿瘤标志物CA153、CA125检验应用的价值。方法统计分析2012年1月-2014年1月本院收治的100例肺癌患者的临床资料。结果观察组患者肿瘤标志物CA153、CA125检测水平异常率分别为54%(54/100)、83%(83/100)均明显比对照组12%(12/100)、17%(17/100)高(P<0.05);CA153+CA125的灵敏度和正确诊断指数均明显比CA153、CA125高(P<0.05);鳞癌患者的血清CA125水平明显比腺癌、小细胞癌患者高(P<0.05),且腺癌患者的血清CA125水平明显比小细胞癌高(P<0.05)。结论肺癌临床诊断中肿瘤标志物CA153、CA125联合检验具有较高的应用价值。
Objective To investigate the value of the detection of tumor markers CA153 and CA125 in the clinical diagnosis of lung cancer. Methods The clinical data of 100 patients with lung cancer admitted from January 2012 to January 2014 in our hospital were statistically analyzed. Results The abnormal rates of tumor markers CA153 and CA125 in observation group were 54% (54/100) and 83% (83/100) respectively, which were significantly higher than those in control group (12% vs 12/100) and 17% (17/100) (P <0.05). The sensitivity and correct diagnosis index of CA153 + CA125 were significantly higher than those of CA153 and CA125 (P <0.05). The serum CA125 level of squamous cell carcinoma was significantly higher than that of adenocarcinoma and small cell carcinoma (P < 0.05). The level of serum CA125 in adenocarcinoma was significantly higher than that in small cell carcinoma (P <0.05). Conclusion The combination of tumor markers CA153 and CA125 in the clinical diagnosis of lung cancer has a high value.